Towards a Better Classification and Novel Therapies Based on the Genetics of Systemic Sclerosis
- 124 Downloads
Purpose of the Review
Nowadays, important advances have occurred in our understanding of the pathogenesis of systemic sclerosis (SSc), which is a rare immune-mediated inflammatory disease (IMID) characterized by vascular damage, immune imbalance, and fibrosis. Its etiology remains unknown; nevertheless, both environmental and genetic factors play a major role in the disease. This review will focus on the main advances made in the field of genetics of SSc.
The assessment of how interindividual genetic variability affects disease onset and progression has enhanced our knowledge of disease biology, and this will eventually translate in the development of new diagnostic and therapeutic tools, which is the final goal of personalized medicine.
We will provide an overview of the most relevant achievements in the genetics of SSc, its shared genetics among IMIDs with special attention on drug repurposing, current challenges for the functional characterization of risk variants, and future directions.
KeywordsScleroderma Genomic medicine Genetic risk factors Susceptibility loci Drug reposition
This work was supported by the Cooperative Research Thematic Network (RETICS) program (RD16/0012/0013) (RIER) from the Health Institute Carlos III (ISCIII) and (SAF2015–66761-P) Spanish Ministry of Economy, Industry and Competitiveness.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 23.•• Genetics for all. Nat Genet, 2019. 51(4): p. 579. This editorial shows how most of the genetic studies haven been carried out in European populations and how this will bias their impact on health in genetically diverse populations. Google Scholar
- 24.• Terao C, Kawaguchi T, Dieude P, Varga J, Kuwana M, Hudson M, et al. Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. Ann Rheum Dis. 2017;76(6):1150–8 This study represents the first transethinic meta-analysis in SSc among European and Asian population, highlighting the potential of studying other populations to find new genetic risk factors in complex diseases.CrossRefGoogle Scholar
- 25.• Gonzalez-Serna D, et al. Analysis of the genetic component of systemic sclerosis in Iranian and Turkish populations through a genome-wide association study. Rheumatology (Oxford). 2019;58(2):289–98 This paper confirms the association of the classical allele HLA-DRB1*11:04 with SSc in several populations. CrossRefGoogle Scholar
- 28.Arnett FC, Gourh P, Shete S, Ahn CW, Honey RE, Agarwal SK, et al. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis. 2010;69(5):822–7.CrossRefGoogle Scholar
- 37.•• Marquez A, et al. Meta-analysis of Immunochip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations. Genome Med. 2018;10(1):97 This study shows the common genetic architecture of SSc with other autoimmune diseases and its potential on drug repositioning. CrossRefGoogle Scholar
- 38.•• Acosta-Herrera M, et al. Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases. Ann Rheum Dis. 2019;78(3):311–9 This paper identifies shared genetics across systemic seropositive rheumatic diseases with functional value and significantly enriched in drug targets, calling our attention on their potential for drug repurposing. CrossRefGoogle Scholar
- 40.• van der Kroef M, et al. Histone modifications underlie monocyte dysregulation in patients with systemic sclerosis, underlining the treatment potential of epigenetic targeting. Ann Rheum Dis. 2019;78(4):529–38 This study is an example of how epigenetic modifications can be targeted for the development of new therapies in SSc. CrossRefGoogle Scholar
- 44.•• Schoenfelder, S., et al., Long-range enhancer-promoter contacts in gene expression control. Nat Rev Genet, 2019. In press. This review goes over the enhancer-promoter interactions in the genome and their impact on development and disease. Google Scholar
- 45.• Martin, P., et al., Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases. Ann Rheum Dis, 2019. In press. This paper is an example of how functional genomics is an effective tool to identify new treatments and drug repurposing in related diseases. Google Scholar
- 51.• Khera AV, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219–24 This paper highlights the impact of stratifying patients at risk based on polygenic risk scores to enable early disease detection and intervention. The authors discuss how genetic prediction should be included into medical care. CrossRefGoogle Scholar